Education
About Us
Working with TipRanks
Follow Us
Aytu BioScience Inc (AYTU)
NASDAQ:AYTU
AYTU Stock Chart & Stats
$2.66
-$0.06(-3.58%)
At close: 4:00 PM EST
$2.66
-$0.06(-3.58%)
Day’s Range― - ―
52-Week Range$0.95 - $3.07
Previous CloseN/A
Volume5.78K
Average Volume (3M)314.73K
Market Cap
$27.10M
Enterprise Value$6.79M
Total Cash (Recent Filing)$32.63M
Total Debt (Recent Filing)$1.86M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Feb 18, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding10,188,208
10 Day Avg. Volume289,104
30 Day Avg. Volume314,725
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.72
Price to Sales (P/S)0.21
P/FCF Ratio-2.65
Enterprise Value/Market Cap0.25
Enterprise Value/Revenue0.11
Enterprise Value/Gross Profit0.16
Enterprise Value/Ebitda-1.24
Forecast
1Y Price Target
$9.33Price Target Upside250.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationEXXUA demonstrated meaningful improvement in depression symptoms while avoiding common sexual dysfunction and appetite-related side effects, which may encourage prescriber preference.
Commercial IntegrationExisting relationships with CNS specialists and psychiatrists and an established field network should ease incorporation of EXXUA into the company's commercial efforts.
Market OpportunityEXXUA targets a $22 billion U.S. prescription market for major depressive disorder, offering substantial upside if clinicians adopt the therapy broadly.
Bears Say
ADHD Franchise VolatilityAnalyst conservatism about continued declines in the ADHD franchise suggests potential downside pressure on overall revenue if that business weakens further.
Generic Competition RiskFuture entry of generic competitors for ADHD products could substantially reduce sales from the existing franchise and increase financial strain.
Reimbursement And Initial UptakeInitial revenue contribution from EXXUA may be muted as inventory stocking and payer reimbursement processes could delay meaningful sales.
Aytu BioScience News
AYTU FAQ
What was Aytu BioScience Inc’s price range in the past 12 months?
Aytu BioScience Inc lowest stock price was $0.95 and its highest was $3.06 in the past 12 months.
What is Aytu BioScience Inc’s market cap?
Aytu BioScience Inc’s market cap is $27.10M.
When is Aytu BioScience Inc’s upcoming earnings report date?
Aytu BioScience Inc’s upcoming earnings report date is Feb 18, 2026 which is in 30 days.
How were Aytu BioScience Inc’s earnings last quarter?
Aytu BioScience Inc released its earnings results on Nov 13, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.11.
Is Aytu BioScience Inc overvalued?
According to Wall Street analysts Aytu BioScience Inc’s price is currently Undervalued.
Does Aytu BioScience Inc pay dividends?
Aytu BioScience Inc does not currently pay dividends.
What is Aytu BioScience Inc’s EPS estimate?
Aytu BioScience Inc’s EPS estimate is -0.41.
How many shares outstanding does Aytu BioScience Inc have?
Aytu BioScience Inc has 10,188,208 shares outstanding.
What happened to Aytu BioScience Inc’s price movement after its last earnings report?
Aytu BioScience Inc reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went up 1.456%.
Which hedge fund is a major shareholder of Aytu BioScience Inc?
Currently, no hedge funds are holding shares in AYTU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aytu BioScience Inc
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
AYTU Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company focused on significant upcoming product launches and managing existing portfolio challenges. While the performance of the ADHD portfolio and progress towards the EXXUA launch highlight growth and strategic focus, declines in certain segments and regulatory concerns pose challenges.View all AYTU earnings summariesAYTU Stock 12 Month Forecast
Average Price Target
$9.33
▲(250.75% Upside)
Technical Analysis
Ownership Overview
4.20% Insiders
1.03% Mutual Funds
28.96% Other Institutional Investors
63.42% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---